Kornimate/medical-research-clean huggingface dataset:
an fmri study of attention and effort after concussion

Conditions: Post Concussive Syndrome

Summary: approximately 1.1 million people a year suffer a mild traumatic brain injury (mtbi), or concussion, in the united states. although most mtbi patients fully recover, as many as 28% have physical, cognitive, and/or emotional symptoms up to 6 months post-injury. when symptoms persist past three months, it is known as post-concussion syndrome (pcs). the cause of pcs is unknown, as structural neuroimaging and neuropsychological (np) testing results are often normal. however, recent functional magnetic resonance imaging (fmri) research in concussed adults showed differences in brain activity compared to controls on working memory tasks, despite normal structural mri and neuropsychological findings. we propose improving this research by assessing brain activation patterns during simple versus complex attention and working memory tasks in 10 concussed adults via fmri. this will be the first study to examine brain activation patterns associated with the degree of effort applied to testing, a factor known to confound interpretation of np test performance. validated computerized measures of selective attention (modified stroop interference task), working memory (n-back), and effort (green's medical symptom validity test; msvt) will be used. ten paid controls will be used for comparative purposes. we hypothesize that concussed patients will show less brain activation than controls on complex versus simple working memory tasks and that activation patterns in concussed patients will generally be lower in those with suboptimal effort. we will also characterize self-reported emotional and physical symptoms in the pcs patients, which has not been done in prior fmri research with this population.


Eligibility criteria:
inclusion criteria: * mild tbi (based on criteria of the american congress of rehabilitation medicine) * aged 18 to 60 * history of non-penetrating head injury * obtaining medical assistance (e.g., personal physician, emergency room) within 24 hours post-injury exclusion criteria: * no prior history of prior post-concussion syndrome (i.e, uncomplicated mild tbi) * moderate to severe tbi * substance dependence * learning disorder * attention-deficit disorder * mental retardation * severe psychiatric disorder requiring hospitalization * previous central nervous system disease * absence of neurosurgery * no evidence of alcohol/drug use related to the injury

Keywords: post concussion syndrome mild traumatic brain injury effort fmri
canine-assisted anxiety reduction in emergency

Conditions: Anxiety

Summary: the purpose of this study is to see if dogs can reduce the anxiety level of patients in the emergency department.

patients will score their pain, anxiety, and depression. a dog will then come into the patient's room for approximately 15 minutes after which the patient will score his/her pain, anxiety, and depression again.

Eligibility criteria:
inclusion criteria: * research staff will screen for inclusion criterion by asking the care providers if they agree with this statement, "i believe this patient is experiencing moderate or greater anxiety". exclusion criteria: * extreme intoxication, agitation that precludes conversation with the patient, fear of dogs, dog bite, allergy to dogs.

Keywords: anxiety dog canine therapy depression pain
preoperative assessment of colon tumor

Conditions: Colorectal Cancer; Colorectal Tumor

Summary: the purpose of this study is to determine whether a colonic tumor can be classified as malignant or benign with magnetic resonance (mr) colonography. patients with a verified colon carcinoma or benign tumor based on diverticulitis are offered a mr colonography with intravenous (i.v.) contrast. the tumor is classified as malignant or benign by assessing the dynamic contrast uptake and morphology. the investigator is blinded from the verified diagnosis and the mr classification is compared to the histological diagnosis.


Eligibility criteria:
inclusion criteria: * colorectal cancer * colorectal tumor exclusion criteria: * active diverticulitis * pacemaker * metal in the body * claustrophobia

Keywords: colorectal cancer colorectal tumor dynamic contrast uptake mr colonography
cetrorelix and ganirelix flexible protocol for (ivf)

Conditions: Infertility/Sterility

Summary: recombinant gonadotropins are currently used for ovarian stimulation in women undergoing to ivf for infertility. recently new flexible protocols have been introduced: the "single dose" and "multiple dose" protocol. the single dose protocol is performed just using cetrorelix by the administration of a single injection of cetrorelix 3 mg subcutaneous when the lead follicle is ≥ 14 mm. the multiple dose protocol consider the daily administration of cetrorelix 0.25 mg subcutaneous or ganirelix 0.25 mg subcutaneous when the lead follicle is ≥ 14 mm and until the realization of hcg criteriathere are few data from letterature about the comparison of the efficacy in pitituary suppression and pregnancy outcome of ganirelix and cetrorelix. objective: to compare the efficacy in pituitary gonadotropin suppression and ivf outcome of multiple dose flexible gonadotrophin-releasing hormone (gnrh) antagonist administration according to follicular size using daily injection of cetrorelix or ganirelix. interventions : patients are randomly assigned in to cetrorelix acetate group or ganirelix acetate group. multiple dose of cetrorelix acetate (0.25 mg) or multiple dose of ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hcg criteria are met.oocyte maturation trigger is performed by the administration of subcutaneous r-hcg (250 μg) or of intramuscular hcg (10,000 iu). after 36 hour transvaginal oocyte retrieval is performed followed by icsi and embrio transfer (72 hours later).


Eligibility criteria:
inclusion criteria : * 18-39 hyears old with regular menstrual cycles (25-35 days in length); * body mass index between 18-29 kg\\m2 * basal follicle-stimulating hormone levels within normal range (\<30 mui\\ml) * absence of clinically relevant anomalies at transvaginal ultrasound examinatio exclusion criteria: * patients affected by grade iii or iv endometriosis according to american society for reproductive medicine (asrm) * history of ovarian hyperstimulation stimulation (ohss) * history of poor response in previous ivf\\icsi cycle: ≤ 3 oocytes retrieved * ≥ 3 prior consecutive ivf\\icsi cycle without a clinical pregnancy.

Keywords: in vitro fertilization gnrh antagonist pituitary suppression
acute presentation of colorectal cancer: an international snapshot

Conditions: Colorectal Cancer

Summary: apollo (acute presentation of colorectal cancer: an international snapshot) is an international, multi-centre, prospective observational study which will address this need and aims to describe the operative and non-operative management of emergency presentations of colon and rectal cancer in an international cohort.

primary aim: describe the variation in the operative and non-operative management of emergency presentations of colon and rectal cancer in an international cohort. secondary aims: * identify risk factors for mortality (intraoperatively, at 30-days and at 90-days) and ostomy rates (at 30- and 90-days) in patients deemed for active management (i.e., not for palliative management) to develop a risk prediction model * validate risk criteria of large bowel obstruction in patients with previously known colorectal cancer undergoing neoadjuvant chemotherapy or awaiting elective surgery who? * patients aged 18 years and above presenting to the hospital acutely with colorectal cancer (crc) for malignant large bowel obstruction (lbo), perforation, crc-related haemorrhage or other reasons within the data collection periods. both those managed with and without surgery will be included * patients with localised and metastatic disease will be included * patients with known colorectal cancer diagnoses will be included if they present acutely (e.g., with disease progression) * patients presenting acutely for the side effects of chemotherapy/radiotherapy of known cancers will be excluded what? data will be collected on patients' presenting status and symptoms, patient management strategies, and intraoperative and postoperative outcomes. when? prospectively over 2023 in consecutive 6-week data collection blocks between january and june with 90-day follow-up till september.

Eligibility criteria:
inclusion criteria: * patient pathology: patients admitted to the hospital acutely with primary colon and/or rectal adenocarcinoma and referred to general/colorectal surgical departments: * patients who are operated on for curative/palliative treatment of colorectal cancer * patients who are referred to general surgery for assessment (irrespective of if they proceed to surgery) * new diagnoses of colorectal cancer * extent of cancer: all patients including extra-abdominal metastatic, intra-abdominal metastatic and non-metastatic disease * known cancer: patients presenting for the first time with colorectal cancer and/or known colorectal cancer diagnosis with progression of disease. i.e. obstruction of known colorectal cancer * patient presentation: symptomatic presentation of colorectal cancer i.e. large bowel obstruction, haemorrhage, perforation exclusion criteria: * presenting for side effects of cancer treatment * patients with secondary cancers * previously included in the study

Keywords: colorectal surgery colorectal cancer colonic stenting emergency surgery
relation between forward head posture and incidence of headache in obese adults

Conditions: Obese; Headache; Neck Pain

Summary: cross sectional study to detect relation between forward head posture and headache. we will take information from the patient about: * detailed history of patient * forward head posture by using mobile application * headache disability index


Eligibility criteria:
inclusion criteria: * obese adult with forward head posture exclusion criteria: * any neurological condition , autoimmune diseases and cervical disc
reducing hot flashes in women using endocrine therapy.

Conditions: Breast Cancer; Hot Flash Due to Medication

Summary: the goal of this randomized intrapatient cross-over study is to assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after breast cancer. the objectives it aims to answer are: * to assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after breast cancer * to assess side effects of oxybutynin versus venlafaxine. * to assess the personal preference of women for oxybutynin versus venlafaxine in reducing hot flashes. * to assess quality of life of women when reducing hot flashes in women using endocrine therapy after breast cancer. participants will fill-out a patient diary during 15 weeks total on a daily basis and receive an (online) questionnaire three times total. researchers will compare two groups (venlafaxine group versus oxubutynine group) to assess its efficacy concerning hot flashes.


Eligibility criteria:
inclusion criteria: * pre-, peri- or postmenopausal women of 18 years or above; * indication for endocrine therapy and already started with tamoxifen, aromatase inhibitors or luteinizing hormone-releasing hormone analogues for at least 4 weeks and planning to continue for the duration of the study; * experiencing hot flashes with a minimum of 14 per week for at least 1 month and desire to start a pharmacologic intervention. exclusion criteria: * pregnant; * breast feeding; * patients who receive chemotherapy or immunotherapy/her2 antibodies within the prior 8 weeks, and patients scheduled for chemotherapy during the study period; * palliative setting; * use of venlafaxine or any other antidepressants, also including st. john's wort within the previous year; * creatinine clearance \< 30 ml/min; * liver cirrhosis; * use of gabapentin and/or calcium channel antagonists within 2 weeks of study entry; * use of oxybutynin before study entry; * use of any other substances or therapies for the treatment of hot flashes, for instance acupuncture.
study to assess the safety, pharmacokinetics, and pharmacodynamics of multiple doses of cor-001

Conditions: Anemia

Summary: this is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of multiple doses of cor-001 or placebo


Eligibility criteria:
inclusion criteria 1. age greater than or equal to 18 years at the time of signing of the icf. 2. the patient agrees to comply with the contraception and reproduction restrictions of the study 3. receiving intravenous (iv) or subcutaneous (sc) erythropoietin stimulating agents (esa) drugs continuously prescribed for a minimum of 8 weeks prior to screening 4. at least 2 ferritin values during screening \> 300 ng/ml 5. at least 2 transferrin saturation (tsat) values during screening between 15% and 50% (inclusive) exclusion criteria: 1. use of systemic immunosuppressive drugs during the screening period or anticipated use of such drugs any time during the study 2. clinical evidence or suspicion of active or smoldering infection by clinical or serologic criteria 3. actively treated or active malignancy 4. known or suspected occult or active bleeding 5. received a red blood cell or whole blood transfusion within 2 months prior to screening or anticipated to receive a blood transfusion at any time during the study
rotavirus vaccine in premature babies

Conditions: Gastroenteritis

Summary: this study will establish the duration of excretion of rotavirus vaccine in stool following vaccination of premature babies hospitalised in a neonatal unit at the time of vaccination.

rotavirus is the commonest cause of severe gastroenteritis in young children, and premature babies are at high risk of serious disease. the rv1 rotavirus vaccine is an altered form of the virus and is given to all children at 8 weeks and 12 weeks of age in the uk. it is given by mouth and excreted in the stool following vaccination - the vaccine virus can therefore be transmitted between people in the same way as the normal virus. premature babies often receive their initial vaccines while they are still hospitalised in neonatal units. there are no data regarding stool excretion of the rv1 rotavirus vaccine in premature babies - there is a theoretical risk of transmission of the vaccine virus to other babies in the unit (if there was inadequate staff hand washing). some countries have therefore advised against immunisation of babies while in the neonatal unit. in the uk, however, the vaccine is being given in neonatal units, enabling evaluation of the vaccine in hospitalised premature babies. this is an observational study of babies admitted to the neonatal unit at the john radcliffe hospital, oxford university hospitals nhs trust who receive their first dose of rotavirus vaccine during their hospital stay.

Eligibility criteria:
inclusion criteria: * participant's parent is willing and able to give informed consent for participation in the study. * current inpatient in the neonatal unit and expected to remain an inpatient for at least 14 days following immunisation with rotavirus vaccine. * due to receive rotavirus vaccination during their admission. * born at less than 37 completed weeks gestation (i.e. up to and including 36 weeks and 6 days) exclusion criteria: • parent is listed on the study delegation log.

Keywords: rotavirus vaccine
safety and efficacy of plant-based diets in hemodialysis patients

Conditions: Renal Disease

Summary: the purpose of this proof-of-concept controlled-feeding study is to evaluate the impact of plant-rich diets, with and without high-potassium fruits and vegetables, on phosphorus and potassium homeostasis in hemodialysis (hd) patients.


Eligibility criteria:
inclusion criteria: * receiving thrice-weekly outpatient hd treatments for end-stage renal disease * 3-month mean serum potassium and phosphorus concentrations of \>4.5 meq/l and \>4.0 mg/dl, respectively * no prior episodes of moderate-severe hyperkalemia (potassium ≥6.5 meq/l) in the past 6 months * deemed appropriate for the intervention by the patient's nephrologist, considering the patient's prognosis, cognition and pending treatments (e.g., kidney transplant) exclusion criteria: * change in medications that alter potassium homeostasis (e.g., raas inhibitors, diuretics, beta-blockers) in the last month * diagnosed with bowel diseases or syndromes (e.g., bowel obstruction, major gi surgery, short-bowel syndrome, irritable bowel syndrome, inflammatory bowel disease, chronic diarrhea) * anemic, defined as a serum hemoglobin concentration \<9.0 g/dl * inadequate dialysis efficacy, defined as a kt/v of \<1.2 * dietary restrictions (e.g., allergies) or otherwise unable/unwilling to adhere to study diets (excludes dietary restrictions on high-potassium foods) * pregnant or planning to become pregnant during the study

Keywords: hemodialysis renal disease
role of frozen section in categorization of thyroid follicular neoplasm

Conditions: Role of Frozen Section in Categorization of Thyroid Follicular Neoplasm

Summary: the goal of this prospective study is to assess the effectiveness of frozen section in distinguishing between benign and malignant tumors in the category of follicular thyroid neoplasm to prevent over-surgery for benign follicular neoplasm (lobectomy vs total thyroidectomy). the main questions, it aims to answer are: the follicular neoplasm is benign or malignent? how far is fnac valid and accurate? researchers will compare the results of frozen section and paraffin embedded sections to evaluate the validity and accuracy of fnac.

thyroid tumors are the most common endocrine neoplasms, with their incidence steadily rising over the past few decades, reaching approximately 8.7 cases per 100,000 people annually in europe. the majority of thyroid tumors are benign accounting for over 90% of cases, whereas malignant thyroid tumors are relatively less common. thyroid cancer represents 1-2% of all newly diagnosed malignancies worldwide, with papillary thyroid carcinoma (ptc) being the most prevalent (80%) followed by follicular thyroid carcinomas (ftc) (15%). fine needle aspiration cytology (fnac) is the primarily diagnostic tool for thyroid nodule. however, its accuracy in distinguishing between benign and malignant follicular neoplasms is limited, necessitating further histopathological evaluation. the bethesda system classifies fnac results into six categories, with follicular neoplasm/suspicious for follicular neoplasm (category iv) carrying a moderate risk of malignancy. differentiating between benign and malignant follicular neoplasms requires assessing capsular and vascular invasion. intraoperative frozen section (fs) has been used for decades to provide rapid histologic assessment guiding the extent of surgery (lobectomy vs total thyroidectomy). however, its utility remains controversial due to variability in diagnostic accuracy and cost-effectiveness. the recent 5th edition of the who classification (2023) categorizes follicular-derived thyroid tumors into benign, low-risk and malignant neoplasms, further refining diagnostic criteria. this study aims to evaluate the accuracy of fnac and fs in diagnosing follicular thyroid neoplasms, optimizing surgical decisions and reducing unnecessary total thyroidectomies in benign cases.

Eligibility criteria:
inclusion criteria: * cases presented with a thyroid nodule, diagnosed as "follicular neoplasm" (bethesda category iv) by fine needle aspiration cytology, and underwent hemi-thyroidectomy. exclusion criteria: * cases with thyroid nodule and diagnosed by fine needle aspiration cytology as non-neoplastic lesions, suspicious for malignancy or as malignant.
survey: clinical outcome after bowel resection in women due to endometriosis

Conditions: Bowel Endometriosis

Summary: endometriosis is one of the most frequent benign diseases that can affect women in their reproductive age. in severe form, the colon or rectum may be involved. it has been shown that the surgical treatment improve typical symptoms like pain and dyspareunia. the investigators evaluated the functional results and quality of life after laparoscopic colonic resection for endometriosis

a clinical analysis of thirty women with typical symptoms including pelvic pain, infertility and endometriotic bowel lesions who underwent laparoscopic surgery including colonic resection performed from 2009 to 2012. quality of life and pain was documented postoperatively. we conduct a telephone survey, which starts at may 2014.

Eligibility criteria:
inclusion criteria: * •clinical diagnosis of endometriosis exclusion criteria: * unwillingness to participate on the survey

Keywords: pain quality of life
smart catheter: a novel biosensor for early detection of catheter associated urinary tract infection

Conditions: Catheter-Associated Urinary Tract Infection

Summary: urinary tract infection (uti) is the most common hospital acquired infection worldwide, and is most commonly associated with catheterisation of the bladder. catheter associated urinary tract infection (cauti) causes increased hospital costs, increased length of stay and increased mortality. this burden of disease is, in part, mediated by a lack of diagnostic and monitoring modalities for cauti. both traditional and novel uti diagnostic tests are susceptible to false positives associated with bacterial colonisation, and correlate poorly with clinically meaningful symptomatic cauti. as such, the current standard of care is reliant on clinical monitoring, which is susceptible to diagnostic delays, over and under treatment. imperial college london have developed a wireless biosensor for continuous monitoring of catheter-urine biochemistry. this project aims to validate this biosensor and demonstrate it's potential for preemptive cauti diagnosis through continuous urinary biochemical monitoring.

this research project aims to demonstrate that continuous urinary biochemical monitoring using a smart catheter biosensor can provide rapid diagnosis of impending catheter associated urinary tract infection (cauti). the primary research question will then be: "does the smart catheter device reduce the time to diagnosis of cauti?" this will be accomplished through four studies: the aim of the first study will be to show the reliability and robustness of the smart catheter device through the question: "is there any difference between the biochemical measurements from the smart catheter device and a gold-standard laboratory measurement?" the aim of the second and third studies aim to demonstrate the different biochemical profiles of infected and healthy urine by addressing the research question: "what is the difference in biochemical concentrations in healthy urine as compared to infected urine?" study 3 will accomplish this by comparing infected human catheter-acquired urine as compared to uninfected human catheter-urine. study 3 will monitor the changes in biochemical changes in an artifical bladder with artificial urine over time while an infection is induced. the final study will demonstrate the reduced time to diagnosis in a clinical setting by addressing the research question: " what is the time difference in diagnosis of cauti from the cauti as compared to the current standard of clinical monitoring?"

Eligibility criteria:
inclusion criteria: * age 18 years or older subjects expected to undergo catheterisation as part of their clinical care. signed informed consent is a prerequisite for inclusion in the study. exclusion criteria: * consent to participate not given known sensitivity to urinary catheters or electronic products patients undergoing urologic procedures

Keywords: biosensor